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OBJECTIVES: To develop the cost data infrastructure to
support a comprehensive, multi-national breast cancer
treatment decision-analysis model. The specifications re-
quired a user-friendly interactive interface for over 70
comparators composed of nearly 350 cost components
used in 24 unique decision trees. The model required an
ability to vary components readily and add new treat-
ments and cost components to multiple trees. METH-
ODS: Since standard decision-analysis software doesn’t
permit categorization of variables or application of the
same variable to multiple decision trees: (1) trees were
programmed in Visual Basic for the interactive interface,
and (2) cost data were loaded into a Microsoft ACCESS
database linked to the trees. Because of this structure, it
was possible to categorize cost data as: 1) Drug Acquisi-
tion and Administration, 2) Adverse Events/Complica-
tions, 3) Concomitant Medications, 4) Hospitalizations,
and 5) Monitoring Costs. For each country in the model,
a separate database was developed with country-specific
costs obtained from standardized databases, government
sources, published literature, and a provider survey. RE-
SULTS: This model was developed for six countries—US,
U.K., Germany, Japan, France, and Italy—and included
clinical and economic variables related to the diagnosis,
treatment, and outcomes of breast cancer. The structure
permits dynamic analyses via varying cost and probabil-
ity scenarios that reflect country-specific treatment prac-
tices and international variations. Each country’s cost da-
tabase applies to four distinct decision trees representing
different stages of breast cancer. The costs can be easily
summarized by category and modified so that multiple
cost components in multiple trees can be varied with one
edit. New cost components can be added to each coun-
try’s database and linked to the trees. CONCLUSION:
When constructing large models (such as disease models)
with several treatments having common cost components
in multiple decision trees, using a categorized cost data-
base linked to the treatment pathways will generate a
user-friendly model with easily-varied cost inputs.
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BACKGROUND: While treatment with 5-fluorouracil
(5-FU) plus leucovorin has been shown to prolong sur-
vival in patients with metastatic colorectal cancer, it also
can cause significant toxicity, sometimes necessitating
hospitalization. The incidence and costs of these admis-
sions have not been fully documented. OBJECTIVE: To
estimate the incidence and cost of hospitalizations for
toxicities associated with 5-FU therapy in patients with
metastatic colorectal cancer. METHODS: Using the
1994 Medicare 5% sample, we identified all patients
with metastatic colorectal cancer who underwent col-
orectal surgery. We stratified these selected subjects into
those who received 5-FU therapy within 90 days of their
surgery (“5-FU group”) and those who did not receive
any chemotherapy (“no-chemotherapy group”); patients
receiving chemotherapeutic agents other than 5-FU were
dropped from the sample. Using techniques of survival
analysis, we then compared the incidence and cost of all
hospital admissions with listed ICD-9-CM diagnosis
codes (principal or secondary) for conditions that may be
related to 5-FU toxicity (e.g., volume depletion, stomati-
tis, nausea and vomiting). RESULTS: A total of 441 pa-
tients met all study entry criteria, including 192 who re-
ceived 5-FU and 249 who did not receive chemotherapy
following surgery. 5-FU patients were significantly
younger than those in the no-chemotherapy group (p 
.001). Mean (SD) follow-up time was slightly longer in
the 5-FU group (137  96 days vs 117  88 days for no
chemotherapy). The incidence at 10.5 months of toxicity-
related hospitalizations (principally volume depletion,
agranulocytosis, gastroenteritis, and nausea and vomit-
ing) was 31% among patients who received 5-FU and
8% among those who did not receive chemotherapy. The
cost of inpatient care was $2,716 higher among 5-FU pa-
tients. CONCLUSIONS: Hospitalization for 5-FU toxic-
ity is frequent and costly among Medicare patients with
metastatic colorectal cancer.
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